OTCMKTS:AVDX - Avant Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0001 0.00 (0.00 %)
(As of 02/20/2019 03:59 AM ET)
Previous Close$0.0001
Today's Range$0.0001 - $0.0001
52-Week Range$0.0001 - $0.0784
Volume12 shs
Average Volume2,817 shs
Market Capitalization$33,696.00
P/E RatioN/A
Dividend YieldN/A
Avant Diagnostics, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic tests that provide information for physicians and patients in the areas of cancers. It offers OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.

Receive AVDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous equipment rental & leasing
Current SymbolOTCMKTS:AVDX



Sales & Book Value

Annual Sales$250,000.00


Net Income$-9,580,000.00


Market Cap$33,696.00
OptionableNot Optionable

Avant Diagnostics (OTCMKTS:AVDX) Frequently Asked Questions

What is Avant Diagnostics' stock symbol?

Avant Diagnostics trades on the OTCMKTS under the ticker symbol "AVDX."

Has Avant Diagnostics been receiving favorable news coverage?

News stories about AVDX stock have been trending positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avant Diagnostics earned a news impact score of 2.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Avant Diagnostics' key competitors?

Who are Avant Diagnostics' key executives?

Avant Diagnostics' management team includes the folowing people:
  • Mr. Jeffrey M. Busch, Exec. Chairman (Age 59)
  • Dr. Michael I. Ruxin, Pres, CEO & Director (Age 73)
  • Mr. Scott VanderMeer, Acting Chief Financial Officer (Age 33)
  • Dr. Glenn D. Hoke Ph.D., Chief Scientific Officer
  • Ms. Rene A. Schena, Chairman & CEO of Arrayit Corp. (Age 56)

How do I buy shares of Avant Diagnostics?

Shares of AVDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avant Diagnostics' stock price today?

One share of AVDX stock can currently be purchased for approximately $0.0001.

How big of a company is Avant Diagnostics?

Avant Diagnostics has a market capitalization of $33,696.00 and generates $250,000.00 in revenue each year. Avant Diagnostics employs 1 workers across the globe.

What is Avant Diagnostics' official website?

The official website for Avant Diagnostics is http://www.avantdiagnostics.com.

How can I contact Avant Diagnostics?

Avant Diagnostics' mailing address is 1050 30TH STREET NW SUITE 107, WASHINGTON DC, 20007. The company can be reached via phone at 708-710-9200 or via email at [email protected]

MarketBeat Community Rating for Avant Diagnostics (OTCMKTS AVDX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Avant Diagnostics and other stocks. Vote "Outperform" if you believe AVDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: What is the NASDAQ?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel